Skip to main content
TipRanks
Go Ultimate75% OFF

Techno Medica Co., Ltd. (6678) AI Stock Analysis

0 Followers
JP:6678

Techno Medica Co., Ltd.

(TSE/TYO:6678)

Select Model
Rating:82Outperform
Price Target:JPY 2,533.00â–²(19.42% Upside)
Action:reiterated
Date:11/18/26

Techno Medica earns a strong overall score driven primarily by its highly attractive valuation, highlighted by a nearly 6% dividend yield and a low P/E ratio. The stock is also supported by robust bullish technical momentum, trading comfortably above all key moving averages. Fundamentally, the company provides a highly stable, zero-debt balance sheet and excellent cash flow generation, which provides a strong safety net despite historically stagnant bottom-line growth.

Positive Factors
Debt-free balance sheetThe absence of reported debt materially reduces financial risk and interest burden, giving Techno Medica flexibility to fund operations and investment internally. Its substantial, stable equity base should also improve resilience through weaker demand or uneven operating periods.
Negative Factors
Uneven revenue growthRepeated year-to-year revenue declines make the company’s growth profile less predictable than its profitability suggests. This uneven trajectory can complicate capacity planning, investment decisions, and earnings forecasting, while requiring the latest rebound to persist before growth can be viewed as durable.

Techno Medica Co., Ltd. (6678) vs. iShares MSCI Japan ETF (EWJ)

-10%0%10%20%30%40%JP:6678+12.64%EWJ+15.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 14.09B
Dividend Yield
6.08%
Average Volume (3M)
12.01K
Price to Earnings (P/E)
12.1
Beta (1Y)
0.53
Revenue Growth
17.11%
EPS Growth
23.02%
Country
Japan
Employees
239
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Techno Medica Co., Ltd. Business Overview & Revenue Model

Company Description

Techno Medica Co., Ltd. is a Japanese company that specializes in the entire lifecycle of in-vitro diagnostic analyzers, covering their research, development, manufacturing, distribution, and international trade. Their product portfolio includes auto...

How the Company Makes Money

Techno Medica primarily makes money by selling in-vitro diagnostic equipment (analyzers and related laboratory systems) to medical institutions and testing laboratories, and by generating recurring revenue from consumables and reagents used with its...

Techno Medica Co., Ltd. Financial Statement Overview

Summary

Techno Medica maintains a highly stable and conservative financial profile. It boasts a pristine, debt-free balance sheet and excellent cash flow generation with high earnings conversion. While recent revenue shows solid double-digit growth, the score is tempered by stagnant long-term net income, slight margin compression, and modest single-digit returns on equity.

Income Statement

65Positive

Balance Sheet

85Very Positive

Cash Flow

80Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue11.59B11.24B9.91B10.28B9.37B9.70B
Gross Profit5.44B5.24B4.88B5.10B4.59B4.78B
EBITDA1.96B1.76B1.40B1.95B1.76B1.96B
Net Income1.19B1.07B1.00B1.35B1.15B1.28B
Balance Sheet
Total Assets15.49B17.97B17.94B17.43B19.44B18.51B
Cash, Cash Equivalents and Short-Term Investments8.44B8.98B9.06B8.59B11.75B11.52B
Total Debt000000
Total Liabilities2.27B3.56B3.55B3.62B3.06B2.86B
Stockholders Equity13.22B14.41B14.39B13.82B16.39B15.65B
Cash Flow
Free Cash Flow01.07B952.67M1.10B748.50M2.00B
Operating Cash Flow01.10B977.53M1.14B887.24M2.06B
Investing Cash Flow0-39.76M-32.34M-100.72M-155.37M2.49B
Financing Cash Flow0-1.15B-470.16M-4.21B-505.09M-598.64M

Techno Medica Co., Ltd. Technical Analysis

Technical Analysis SentimentNeutral
Last Price2121.00

Price Trends

50DMA2068.40Positive
100DMA2058.19Positive
200DMA2149.11Negative

Market Momentum

MACD26.67Positive
RSI50.74Neutral
STOCH37.37Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6678, the sentiment is Neutral. The current price of 2121.00 is below the 20-day moving average (MA) of 2136.35, above the 50-day MA of 2068.40, and below the 200-day MA of 2149.11, indicating a neutral trend. The MACD of 26.67 indicates Positive momentum. The RSI at 50.74 is Neutral, neither overbought nor oversold. The STOCH value of 37.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:6678.

Techno Medica Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:6678 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:6678JP:667882OutperformJPY 18.29B12.06―6.08%17.11%23.02%
JP:6849JP:684963NeutralJPY 254.11B20.24―2.11%-0.18%-33.38%
JP:6523JP:652361NeutralJPY 163.74B11.338.71%3.27%2.74%145.33%
JP:7963JP:796359NeutralJPY 8.15B9.85―3.02%8.56%7.14%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4549JP:454950NeutralJPY 73.85B40.27―2.55%3.92%-52.01%
JP:7600JP:760045NeutralJPY 8.06B-5.03―5.56%-8.68%-75.03%

* Healthcare Sector Average

Performance Comparison

0%50%100%JP:6678JP:6523JP:4549JP:6849JP:7600JP:7963Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:6678 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:6678Techno Medica Co., Ltd.2121.00257.4213.81%
JP:6523PHC Holdings Corp.1286.00348.5837.18%
JP:4549Eiken Chemical Co., Ltd.2273.0044.341.99%
JP:6849Nihon Kohden Corporation1519.0038.532.60%
JP:7600Japan Medical Dynamic Marketing, Inc.306.00-149.23-32.78%
JP:7963Koken Ltd.1650.00-152.47-8.46%

Techno Medica Co., Ltd. Corporate Events

Techno Medica Reports Strong First-Half Earnings Growth

Nov 6, 2026

Techno Medica Co., Ltd., a Tokyo-listed company, reported non-consolidated net sales of ¥4.453 billion for the six months ended September 30, 2026, up 8.5% year on year, while operating profit rose 75.7% to ¥468 million and net profit increased 58.2%...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026